Xinxiang Tuoxin Pharmaceutical Co.Ltd. Asset Resilience Ratio
Xinxiang Tuoxin Pharmaceutical Co.Ltd. asset resilience ratio. Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) has an Asset Resilience Ratio of 7.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 301089 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Xinxiang Tuoxin Pharmaceutical Co.Ltd. (2021–2025)
Asset resilience ratio of Xinxiang Tuoxin Pharmaceutical Co.Ltd. from 2021 to 2025. This chart shows how Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s Asset Resilience Ratio has changed over time. Read debt load of Xinxiang Tuoxin Pharmaceutical Co.Ltd. for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Xinxiang Tuoxin Pharmaceutical Co.Ltd. balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥115.56 Million | 7.0% |
| Total Liquid Assets | CN¥115.56 Million | 7.00% |
Asset Resilience Insights
- Limited Liquidity: Xinxiang Tuoxin Pharmaceutical Co.Ltd. maintains only 7.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. Industry Peers by Asset Resilience Ratio
Compare Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Xinxiang Tuoxin Pharmaceutical Co.Ltd. Asset Resilience Ratio by Year (2021–2025)
Xinxiang Tuoxin Pharmaceutical Co.Ltd. asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Xinxiang Tuoxin Pharmaceutical Co.Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.31% | CN¥105.15 Million ≈ $15.39 Million |
CN¥1.67 Billion ≈ $243.69 Million |
-7.95pp |
| 2024-12-31 | 14.27% | CN¥250.88 Million ≈ $36.71 Million |
CN¥1.76 Billion ≈ $257.29 Million |
+3.90pp |
| 2023-12-31 | 10.37% | CN¥190.70 Million ≈ $27.91 Million |
CN¥1.84 Billion ≈ $269.10 Million |
-2.66pp |
| 2022-12-31 | 13.03% | CN¥240.16 Million ≈ $35.14 Million |
CN¥1.84 Billion ≈ $269.73 Million |
-2.80pp |
| 2021-12-31 | 15.83% | CN¥220.62 Million ≈ $32.28 Million |
CN¥1.39 Billion ≈ $203.94 Million |
-- |
About Xinxiang Tuoxin Pharmaceutical Co.Ltd.
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, cytosine, 5-fluorocytosine, cytidine, uridine; an… Read more